ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1359	National Cancer Institute	Html	en	Cancer Pain (PDQ®)–Health Professional Version	Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed.	initial pain assessment 0.567168 baseline pain intensity 0.558291 treats mild pain 0.559952 moderate cancer pain 0.617809 metastatic bone pain 0.57198 incident cancer pain 0.559612 acute pain resolves 0.55829 pain management treatment 0.568663 ongoing pain management 0.552517 pain relief ladder 0.55951 common cancer pain 0.591113 Neuropathic Pain sections 0.560808 somatic pain 0.561569 indicates mild pain 0.560721 cancer patients 0.628525 pain intensity 0.56637 pain management 0.652391 neuropathic pain 0.592568 Pain Symptom Manage 0.699092 cancer pain control 0.556765 Pain Management Nursing 0.556277 Pain Physician 0.561182 pain assessment 0.597079 Pain Palliat Care 0.567356 breakthrough cancer pain 0.563775	visceral pain signals 0.562249 severe cancer pain 0.582593 PUBMED Abstract 0.564761 visceral pain 0.565502 pain assessment toolkit 0.554382 mild pain 0.57672 Effective pain management 0.567467 cancer pain management 0.592002 pain relief 0.569023 moderate pain 0.568137 cancer pain 0.834476 American Pain Society 0.557173 pain 0.954306 acute pain 0.572092 Abstract 0.595673 Pain Med 0.572479 Clin Oncol 0.552396 severe pain 0.584777 cancer pain experience 0.579997 pain scale 0.566028 pain levels 0.565618 comprehensive pain assessment 0.576005 indicates moderate pain 0.564768 pain receptors 0.555011	CLICK HERE
1410	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	Surgical Adjuvant Breast 0.47836 Obstet Gynecol 0.483376 World Cancer Research 0.452806 endometrial carcinoma 0.52954 Engl J Med 0.456388 American Cancer Society 0.497798 Br J Cancer 0.455416 case-control study 0.441437 Int J Cancer 0.478131 early-stage breast cancer 0.461817 intentional weight loss 0.529248 breast cancer treatment 0.473891 breast cancer patients 0.472714 body mass index 0.470175 endometrial cases 0.529694 Cancer Causes Control 0.452081 Natl Cancer Inst 0.529481 lower endometrial cancer 0.563354 postmenopausal endometrial cancer 0.554715 modifiable risk factor 0.44186 endometrial cancer 0.948645 invasive breast cancer 0.472622 Cancer Treat Rep 0.454232 et al. 0.498732	early breast cancer 0.472532 tamoxifen-treated breast cancer 0.462067 nonpolyposis colorectal cancer 0.457467 endometrial cancer cases 0.601622 polycystic ovarian syndrome 0.445837 Cancer Epidemiol Biomarkers 0.47249 endometrial cancer risk 0.82277 Cancer Facts 0.44862 PUBMED Abstract 0.515106 Nutr Cancer 0.444116 widespread endometrial cancer 0.555715 Epidemiol Biomarkers Prev 0.442397 endometrial cancer incidence 0.612962 Breast Cancer Prevention 0.475561 African American women 0.440785 invasive gynecologic cancer 0.464853 postmenopausal women 0.497969 Abstract 0.52778 breast cancer 0.526041 adjuvant tamoxifen 0.441172 physical activity 0.445711 Breast Cancer Study 0.467445 breast cancer incidence 0.479289 National Surgical Adjuvant 0.475167	CLICK HERE
1501	National Cancer Institute	Html	en	Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.	nodular sclerosis hodgkin 0.365708 refractory pediatric Hodgkin 0.351319 refractory Hodgkin 0.416042 early Hodgkin lymphoma 0.394054 Hodgkin lymphoma cases 0.403293 Hodgkin disease-added value 0.362383 early-stage hodgkin lymphoma 0.391985 lymphocyte-predominant hodgkin 0.393688 Radiat Oncol Biol 0.45608 risk Hodgkin lymphoma 0.399452 favorable-risk Hodgkin lymphoma 0.388818 Hodgkin lymphoma histology 0.402552 pediatric hodgkin lymphoma 0.479624 German-Austrian Pediatric Hodgkin 0.419443 classic Hodgkin lymphoma 0.417403 pediatric Hodgkin disease 0.379402 high-risk Hodgkin lymphoma 0.432447 Hodgkin Study Group 0.371284 sclerosis Hodgkin lymphoma 0.410888 newly diagnosed Hodgkin 0.350548 Hodgkin lymphoma treatment 0.38529 childhood hodgkin lymphoma 0.384013 familial classical Hodgkin 0.365775 lymphocyte-predominant Hodgkin lymphoma-experience 0.349402 childhood hodgkin 0.486255	cancer survivor study 0.348591 et al. 0.539517 lymphocyte-rich classical Hodgkin 0.347809 pediatric hodgkin 0.578037 intermediate-risk hodgkin lymphoma 0.423631 advanced Hodgkin lymphoma 0.416897 refractory Hodgkin lymphoma 0.395506 PUBMED Abstract 0.412711 unfavorable pediatric Hodgkin 0.351719 Hodgkin lymphoma subtype 0.402744 Lymphocyte-predominant Hodgkin lymphoma 0.388987 advanced-stage Hodgkin 0.357413 lymphocyte predominant Hodgkin 0.374597 Abstract 0.561102 Clin Oncol 0.905331 Hodgkin Lymphoma Group 0.412086 classical Hodgkin lymphoma 0.427321 Oncol Biol Phys 0.463188 Hodgkin disease 0.410937 childhood cancer survivor 0.348315 unfavorable childhood Hodgkin 0.356068 hodgkin lymphoma 0.82441 recurrent Hodgkin lymphoma 0.392381 predominant Hodgkin lymphoma 0.394303	CLICK HERE
1513	National Cancer Institute	Html	en	Pancreatic Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic cancer.	pancreatic carcinoma E6201 0.398831 unresectable pancreatic carcinoma 0.359985 pancreatic malignancy 0.311753 Engl J Med 0.337007 Ann Surg 0.317423 German CONKO-study group 0.318318 phase iii trial 0.413157 pancreatic tumors 0.328586 der Schelling GP 0.325496 randomized phase 0.350612 advanced pancreatic adenocarcinoma 0.470438 randomized trial 0.376847 patients 0.470655 investigational new drug 0.321651 Cooperative Oncology Group 0.454021 van der Schelling 0.325555 Moore MJ 0.343635 fixed-dose rate infusion 0.313379 pancreatic carcinoma 0.542646 Ann Oncol 0.304631 et al. 0.690156 Best supportive care 0.315629 study 0.356854 Expandable metal stents 0.329142	phase ii trial 0.320548 Hammel et al. 0.336299 Oncology Group study 0.328761 Clinical Trials Group 0.319844 gemcitabine-based induction chemotherapy 0.328647 National Cancer Institute 0.337583 den Bosch RP 0.325608 advanced unresectable pancreatic 0.366836 metastatic pancreatic cancer 0.353118 advanced pancreatic cancer 0.926655 advanced pancreatic carcinoma 0.404683 unresectable periampullary adenocarcinoma 0.332936 first-line therapy 0.306838 van den Bosch 0.324595 refractory pancreatic cancer 0.407704 advanced pancreas cancer 0.35576 Abstract 0.559395 Clin Oncol 0.91428 unresectable pancreatic cancer 0.410252 Canada Clinical Trials 0.318756 Eastern Cooperative Oncology 0.46104 drug treatment program 0.320206 gemcitabine 0.380059 active chemotherapy regimens 0.332336	CLICK HERE
3421	National Cancer Institute	Html	es	Antioxidantes y prevención del cáncer	Antioxidants are substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. Antioxidants interact with and stabilize free radicals and may prevent some of the damage fre	nutrition intervention trial 0.318966 Population Nutrition Intervention 0.307215 Minerales Antioxidantes 0.329026 mortality during 0.312847 skin cancers 0.309111 Hercberg S 0.31386 complementos antioxidantes alimenticios 0.358441 vitamina c 0.306663 vitamina a 0.307237 Klein EA 0.307093 vitamina e 0.306864 Virtamo J 0.307865 mortality after 0.306705 antioxidantes alimenticios 0.533634 stopping antioxidant vitamins 0.315828 Internal Medicine 0.308526 Estados Unidos 0.333664 antioxidant vitamins 0.315879 PubMed Abstract 0.94039 Estudio Demográfico 0.30775 follow-up after stopping 0.328778 after stopping antioxidant 0.315902 skin cancers during 0.306731 minerales selenio 0.30885 health beneficial effects 0.308495	randomized controlled 0.317735 International Journal 0.310662 health effects 0.306579 Kristal AR 0.308705 tomar complementos 0.660547 Taylor PR 0.316391 Ezzedine K 0.307269 general population 0.307041 supplemental alpha-tocopherol 0.309241 Kesse-Guyot E 0.307458 tract cancers 0.32431 médicos varones 0.307704 beta carotene 0.315537 elemento mineral selenio 0.311109 Cancer Prevention Study 0.31922 Cancer Prevention Trial 0.339926 complementos alimenticios 0.353561 retinol efficacy trial 0.343648 SU.VI.MAX Study 0.30914 radicales libres 0.808852 resultados mixtos 0.310828 Cancer Institute 0.352968 New England Journal 0.317494 Cancer Prevention 0.362527	CLICK HERE
3565	National Cancer Institute	Html	en	Funding Opportunities	Find a wide range of funding announcements to support cancer research and training, organized by topic and by funding mechanism.	population sciences 0.493717 promising research areas 0.56879 research grants 0.500944 AIDS-related cancer 0.494918 Cancer Clinical Proteomics 0.567175 Cancer Complementary 0.503257 mutant RAS-driven cancers 0.494379 Cancer Moonshot Blue 0.59594 Cancer Nanotechnology Research 0.679363 Cancer program 0.497422 research community 0.507936 cancer patients 0.484719 Research projects 0.502551 Basic cancer research 0.680007 Tissue Sample Collection 0.485994 Reduce Cancer Health 0.579079 Trans-NIH Research Project 0.629695 Cancer Health Disparities 0.713271 surveillance cancer research 0.666086 basic cancer biology 0.601818 Cancer Control 0.538781 biostatistical funding opportunities 0.51758 Cancer Moonshotâ„  Funding 0.624526 Ribbon Panel recommendations 0.479686	cancer prevention 0.563482 Cancer Treatment 0.485294 epidemiological research 0.487712 alternative medicine practice 0.49686 NCI Alliance 0.464504 Provocative Questions Program 0.51458 cancer research 0.973473 treat cancer 0.476905 recent NCI-supported RFAs 0.522382 cancer screening procedures 0.560144 alternative medicine 0.550525 Analysis Technologies Program 0.493099 small business 0.635559 private sector participation 0.462098 health disparities perspective 0.521069 RAS Initiative enlists 0.522897 Outstanding Investigator Award 0.657445 NCI initiative 0.486583 Biospecimen Research Branch 0.595175 Business Innovation Research 0.566067 Translational Research 0.497403 Business Technology Transfer 0.60463 Small Business Technology 0.604737 research communities 0.503329	CLICK HERE
3670	National Cancer Institute	Html	es	Estudio TAILORx indica que mujeres con riesgo bajo de recurrencia de cáncer de seno pueden abstenerse de quimioterapia	Resumen de resultados del estudio TAILORx indica que mujeres con cáncer de seno receptor de hormonas en estadio inicial tienen un riesgo bajo de recurrencia según una prueba de expresión de 21 genes.	Assigning Individualized Options 0.731016 NIC-Clinical Trials Group 0.677172 Therapy Evaluation Program 0.674291 quimioterapia adyuvante mejora 0.979078 doctor joseph sparano 0.667749 doctora jo anne 0.660047 llamada puntuación 0.615517 Estados Unidos 0.857653 NRG Oncology 0.56481	excelentes resultados 0.548811 cuáles mujeres 0.873744 Oncotype DX® 0.57646 invasivo enfermedad 0.55814 New England Journal 0.693093 Clinical Oncology 0.572538 Nueva Zelanda 0.530968 estudio tailorx 0.733998	CLICK HERE
16838	National Cancer Institute	Html	en	University of Texas — Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology	The focus of the University of Texas MD Anderson Cancer Nanotechnology Training Center is presented here.	unique boot camp 0.665183 lab management skills 0.648892 Rice University 0.515834 M.D. 0.338543 Objectives 0.334693 MD Anderson 0.892403 preparation 0.332958 independent careers 0.500052 problem 0.335383 MD Anderson CNTC 0.66004 Ph.D. 0.338612 seminar experiences 0.507875 translational research 0.966631 academic labs 0.516268 hands-on coursework 0.547621 project management 0.489839 Konstantin Sokolov 0.587384 future leaders 0.517794 independent research project 0.702082 Texas 0.33468 cancer nanotechnology 0.891595 translational research projects 0.795763 training program 0.532137 multidisciplinary mentorship 0.538033 post-doctoral training 0.533942	trainees 0.545607 specific interests 0.517161 Rebecca 0.339233 research fellowship grant 0.692269 multidisciplinary field 0.50801 Ph.D 0.333304 cancer translational research 0.824834 Cancer Management 0.515303 gap 0.336671 Principal Investigator 0.540969 Didactic coursework 0.550767 completion 0.335106 Center 0.334629 MD Anderson Cancer 0.714625 NCI Nanotechnology Characterization 0.789772 program faculty mentors 0.704052 current opportunities 0.49661 federal resources 0.494134 new discoveries 0.52212 Sunil Krishnan 0.581597 deep understanding 0.497785 barriers 0.38628 introductory course 0.486248 Training Focus 0.539936	CLICK HERE
17188	National Cancer Institute	Html	en	Fertility Issues in Boys and Men with Cancer	Fertility issues are common in boys and men getting cancer treatment. Fertility preservation options include sperm banking, testicular shielding, testicular sperm extraction (TESE), and testicular tissue freezing. Support and clinical trials are listed.	Sexual Health Issues 0.508548 cancer treatment 0.619036 fertility 0.97146 baseline fertility 0.628851 family member 0.464194 cancer therapy 0.481706 health care team 0.501109 sperm counts 0.505642 fertility problems 0.606189 stem cell transplants 0.576694 upsetting long-term effects 0.50079 Sperm banking 0.500128 Testicular tissue freezing 0.505046 specific treatment 0.473076 fertility clinic 0.610475 professionally led support 0.49722 sperm-forming cells 0.50982 reproductive endocrinologist 0.471953 fertility options 0.634938 fertility preservation procedures 0.624595 Testicular sperm extraction 0.553558 radiation therapy 0.551741 testicular shielding 0.519544 sperm cells 0.508932 Reproductive Medicine 0.463459	cancer treatments 0.62693 blood stem cell 0.500463 personal health factors 0.507399 fertility preservation options 0.794614 testicular tissue cryopreservation 0.506676 scatter radiation 0.468354 male cancer patients 0.603613 fertility preservation 0.823931 young male cancer 0.600402 fertility risks 0.574477 LIVESTRONG Fertility 0.586472 rectal cancer 0.479468 reproductive age 0.463816 sperm 0.578609 infertility 0.495824 doctor 0.471639 fertility specialist 0.642942 reproductive medical information 0.506006 cancer 0.662671 fertility preservation clinic 0.634592 fertility preservation discounts 0.62021 bone marrow transplants 0.501862 child’s doctor 0.462088 reproductive organs 0.558126	CLICK HERE
17278	National Cancer Institute	Html	es	Preparación para cuidar a un enfermo con cancer	Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Las personas que cuidan a pacientes deben estar al tanto de muchas cosas y planificar el cuidado de su ser querido.	dándoles oportunidad 0.826428 !No hables así¡ 0.973126 Nueva York 0.867641 principales formas 0.895606 Oxford University 0.86575	Lynna J 0.87542 busque consejo 0.895137 mejores tratamientos 0.878203 surgen preguntas 0.922072	CLICK HERE